Sinovac vaccination and the course of COVID-19 disease in hospitalized patients in Turkey

Annals of Saudi Medicine - Tập 42 Số 3 - Trang 147-154 - 2022
Leman Acun Delen1, Mesut Öterkuş2
1From the Department of Anesthesiology and Reanimation, Malatya Education and Research Hospital, Malatya, Turkey
2From the Department of Anesthesiology and Reanimation, Malatya Turgut Özal University, Malatya, Turkey

Tóm tắt

BACKGROUND: The Alpha variant of SARS-CoV-2 has a higher transmission rate than the first variant identified. The efficacy of vaccines is affected by the characteristics of SARS-CoV-2 variants. OBJECTIVE: Investigate the relationship of vaccination and virus variant on the course of the disease in patients who were hospitalized with a diagnosis of COVID-19. DESIGN: Retrospective, cohort study SETTING: Tertiary health institution PATIENTS AND METHODS: The study included patients older than the age of 18 years who were hospitalized in a COVID-19 service or the intensive care unit with a diagnosis of COVID-19 between 1 January 2021 and 30 April 2021. Demographic characteristics, vaccination and the Alpha virus variant status, comorbidities, and information about hospitalization were obtained from the hospital automation system and patient files. MAIN OUTCOME MEASURES: Vaccination rate and relationship with course of disease. SAMPLE SIZE: 608 RESULTS: Most of the patients (n=482, 79.3%) were admitted to the COVID-19 service. More of the COVID-19 service patients had the Alpha variant than the patients admitted to ICU ( P <.009). The Alpha variant was also more common in younger patients ( P <.001). There was no relationship between the Alpha virus and comorbid diseases such as diabetes mellitus and hypertension. Mortality was lower in the patients who had received a second dose of the Sinovac vaccine ( P =.004) compared with unvaccinated patients. CONCLUSION: Although the Alpha variant spreads faster, it has a milder course. If only the Sinovac vaccine is available, we recommend that the two doses of the Sinovac vaccine be administered. LIMITATIONS: Our study is single-center and did not include pregnant and pediatric patients. CONFLICT OF INTEREST: None.

Từ khóa


Tài liệu tham khảo

10.1001/jama.2020.1585

10.1056/NEJMoa2002032

10.1111/joim.13089

10.1111/all.14238

Worldometer: Coronavirus (https://www.worldometers.info/coronavirus/)

COVID-19 Bilgilendirme Platformu (https://covid19.saglik.gov.tr).

10.1111/tmi.13383

10.23812/21-3-E

10.1016/j.bbadis.2020.165878

10.1016/j.actatropica.2020.105778

10.1016/j.ygeno.2020.09.028

10.1016/j.cell.2021.03.052

Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). 2021 Apr 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 34033342.

Davies NG Barnard RC Jarvis CI Kucharski AJ Munday J Pearson CAB et al. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. MedRxiv.2020.12.24. 20248822. doi: 10.1101/2020.12.24.20248822

10.1016/j.dsx.2020.03.012

10.3390/ijms22041695

10.1016/j.ijid.2020.05.071

10.3390/v13030392

10.1016/j.cell.2020.06.043

Davies NG Jarvis CI CMMID COVID-19 Working Group Jewell NP Diaz-Ordaz K Keogh RH et al. Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01. Preprint. medRxiv. 2021;2021.02.01.21250959. doi: 10.1101/2021.02.01.21250959

10.1016/j.ebiom.2020.103112

10.1016/j.bbrc.2020.10.109

10.1038/s41586-021-03470-x

10.1002/jmv.25889

10.24938/Kutfd.810344

10.3390/v12050526

10.23812/21-3-E

10.1080/21645515.2020.1820808

10.1016/S0140-6736(20)32623-4

10.1016/S1473-3099(20)30773-8

Thông tin
Thông tin xuất bản

Annals of Saudi Medicine

Tập 42 Số 3

147-154

Thông tin tác giả